Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS)

Klinische Padiatrie

Volumn 219, Issue 6, 2007, Pages 318-322

  Bernbeck, B ^a,c   Bahci, S ^a   Meisel, R ^a   Troeger, A ^a   Schonberger S ^a   Laws, H J ^a   Kramm, C ^a   Wessalowski, R ^a   Koscielniak, E ^b   Dilloo, D ^a   Gobel U ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b OLGAHOSPITAL   (Germany)

^c KLINIKUM DORTMUND   (Germany)

Author keywords

Autologous hematopoietic stem cell support; High risk soft tissue sarcoma; TECC chemotherapy

Indexed keywords

C REACTIVE PROTEIN; CARBOPLATIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MEROPENEM; NAVELBINE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TOPOTECAN; TROFOSFAMIDE; VINBLASTINE;

ADD ON THERAPY; ADOLESCENT; ADULT; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CD34 SELECTION; CHILD; CLINICAL ARTICLE; CLINICAL INDICATOR; CONTINUOUS INFUSION; ERYTHROCYTE; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; INFECTION; LUNG METASTASIS; MAINTENANCE THERAPY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PYREXIA IDIOPATHICA; SOFT TISSUE SARCOMA; SURVIVAL TIME; THROMBOCYTE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM, RESIDUAL; REMISSION INDUCTION; SARCOMA; TIME FACTORS; TOPOTECAN; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 36949040572     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-985896     Document Type: Article

References (26)

1. Ackermann B, Tröger A, Glouchkova L, Körholz D, Göbel U, Dilloo D. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klin Pädiatr 2004; 216: 176-182
2. Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001; 23: 225-233
3. Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E, Koscielniak E, Treuner J, Pinkerton CR. High-Dose Melphalan With Autologous Stem-Cell Rescue in Metastatic Rhabdomyosarcoma. J Clin Oncol 1999; 17: 2796-2803
4. Diffoo D, Niemeyer C, Suttorp M, Vormoor J. Dauer der Einlagerung autologer Blutstammzellprodukte von Kindern und Jugendlichen mit malignen Erkrankungen. Klin Pädiatr 2005; 217: 371-373
5. Ernestus K, Pietsch T, Gessler M, Simon T, Hero B, Berthold F. Biomaterialbanken für embryonale Tumoren: Struktur, Nutzen und Risiken. Klin Pädiatr 2006; 218: 132-138
6. Hale GA. Autologous hematopoietic stem cell transplantation for pediatric solid tumors. Expert Rev Anticancer Ther 2005; 5: 835-846
7. Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2006; 47: 790-794
8. Kaatsch P, Spix C. Annual Report 2005. German Childhood Cancer Registry 2005
9. Klingebiel T, Pertl U, Hess CF, Jürgens H, Koscielniak E, Pötter R, Heek-Romanowski R van, Rossi R, Schott C, Spaar HJ, Willnow U, Treuner J. Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol 1998; 30: 269-275
10. Klingebiel T, Bader P, Hollatz G, Koehl U, Lehrnbecher T, Meisel R, Dilloo D. Immunotherapy in children: report from the Reisensburg-Symposium October 20-22, 2004 and recent advances. Klin Pädiatr 2006; 218: 355-365
11. Koscielniak E, Jürgens H, Winkler K, Bürger D, Herbst M, Keim M, Bernhard G, Treuner J. Treatment of soft tissue sarcoma in childhood and adolescence. Cancer 1992; 70: 2557-2567
12. Koscielniak E, Klingebiel TH, Peters C, Hermann J, Burdach ST, Bender-Götze C, Müller-Weihrich ST, Treuner J. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 227-231
13. Koscielniak E. Autologous haematopoietic stem cell transplantation in childhood solid tumours. Rep Pract Oncol Radiotherp 2000; 5: 49-55
14. Koscielniak E. Soft tissue sarcoma in children. Diagnosis and therapeutic modalities. Editorial. Adv Clin Exp Med 2001; 10: 3-8
15. Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Paediatr Drugs 2002; 4: 21-28
16. Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006; 24: 3415-3422
17. Lang P, Pfeiffer M, Müller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Foll J, Martin D, Handgretinger R. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Pädiatr 2006; 218: 321-326
18. Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, Ludwig WD, Riehm H, Schrappe M. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Pädiatr 2005; 217: 310-320
19. Pappo AS, Lyden E, Breneman J, Wiener E, Teot L, Meza J, Crist W, Vietti T. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma Study. J Clin Oncol 2001; 19: 213-219
20. Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, Raney RB, Womer RB, Parham DM, Qualman SJ, Grier HE. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 1999; 17: 3487-3493
21. Reichardt P, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, Kanz L, Hartmann JT. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 2003; 21: 481-486
22. Sandler E, Lyden E, Ruymann F, Maurer H, Wharam M, Parham D, Link M, Crist W. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001; 37: 442-448
23. Treuner J, Koscielniak E. CWS 2002 P Cooperative Weichteilsarkomstudie der Gesellschaft für Pädiatrische Onkologie und Hämatologie korrigierte Fassung vom 23.10.2003
24. Winkle P van, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005; 44: 338-347
25. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol 2004; 22: 1398-1403
26. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engen J, Harms D, Göbel U. An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Pädiatr 2003; 215: 303-309